A B S T R A C T To examine the role of basal insulin and glucagon secretion in potassium and sodium homeostasis, somatostatin, a potent inhibitor of insulin and glucagon secretion, was infused for 5 h into healthy human subjects, maturity-onset diabetes, juvenile-onset diabetics, and normal dogs. Infusion of somatostatin resulted in an increase in serum potassium (0.5-0.6 meq/liter) in normal subjects and maturity-onset diabetics, but not in juvenile-onset diabetics despite equivalent reductions in plasma glucagon in all three groups. A similar rise in serum potassium was observed in normal conscious dogs given somatostatin and was reversed by insulin replacement. Urinary excretion of potassium was unaffected by somatostatin.
INTRODUCTION
The regulation of body potassium balance is considered to be primarily determined by the adrenal cortex and the kidneys (1, 2) . The rate of urinary excretion of potassium is influenced by the secretion of aldosterone (3) and the pericapillary potassium concentration bathing the distal and collecting tubules (4) . With respect to circulating levels of potassium, it has also long been recognized that physiologic increases in plasma insulin will lower the serum potassium concentration by stimulating cellular uptake of this ion in muscle (5) and liver tissue (6) . In addition, the disposal of large exogenous loads of potassium, which are capable of stimulating insulin secretion in normal subjects (7) (8) (9) , is reduced in the diabetic state (9) (10) (11) . However, whether or not basal levels of insulin (as observed in the postabsorptive state) influence endogenous potassium homeostasis or the disposal of small exogenous loads of potassium has not been established. Furthermore, although increases in insulin have been shown to have an antinatriuretic effect (12, 13) and since a natriuretic action has been ascribed to hyperglucagonemia (14) , whether or not basal levels of these hormones influenice urinary sodium excretion has not been determined. In the present study the role of basal insulin and glucagon secretion in potassium and sodium homeostasis was examined by administering somatostatin, a potent inhibitor of insulin and glucagon secretion (15) .
MIETHODS

Humnatn studies
Studies xvere undertaken in three groups of subjects: (a) ninle healthx nonobese volunteers, 20 -38 yr of age; (b) six maturity-onset diabetics, 41-60 yr of age, with fasting plasmna glucose levels of 121-285 mg/10() nil who were beiing mainaged with diet aloine; anid (c) three juvenileonset diabetics, (insulin-dependenit) 31 Priiiiiiig doses of inuliii (40 img/kg body wt) and p-amiiohippurate (PAH)' (12 nig/kg bodyI wt) were giveii intravenously and sustaininig iiifusions of inuliin and PAH in 0.9% sodium chloride were adniinistered at a rate of 0.5 ml/min throughout the study to maintaiii plasma levels of 20 aiid 2.0 mg/nil, respectively. Imnmediately after the insertioii of the intravenous catheters 500 nil of iiornial saline was infused over 30 iiin to ensure an adequate uriiie output. After a 60-miii equilibration period, two 30-niin control urine samples were collected. The dogs theii received either potassiumii chloride (0.375 me(l/kg per h) alone for 4 h, or cyclic soniatostatin (0.2 aug/kg per min) and potassiuni chloride (0.375 nieq/kg per h). Blood and uriiie saniples were collected at 30-niin iiitervals throughout the studv. The volumlle of blood withdrawii was replaced quantitatively with iiornial saline to avoid volunie depletion. Each dog received both inifu-ision protocols at 7-to 10-day intervals. The order of studies was ran(loniizecl.
Analytical methods
Seruni aiid uriiie potassiuiiii anid sodiumii conicentratioiis were deteriiiiiied bl flaiiie photometry using lithiumll as aii Abbreviatiotn used inl this paper: PAH, p-amiinohippurate.
Insulin anid Potassiumt Homneostasis internal standard (Flame Photometer 143, Instrumentation Laboratory, Inc., Lexington, Mass.) Plasma and urine PAH concentrations were measured by the method of Smith (17) using a Gilford spectrophotometer at 540 nm (Gilford Instrument Laboratories Inc., Oberlin, Ohio). Inulin concentrations in plasma and urine were quantitated by the method of Walser et al. (18) adapted to the AutoAnalyzer (Technicon Instruments Corp., Tarrytown, N. Y.) by Fuhr et al. (19) . Serum and urine creatinine was measured by the method of Folin and Wu (20) adapted to the AutoAnalyzer. Plasma insulin was determined by radioimmunoassay with the use of talc to separate free from bound insulin (21) . Plasma glucagon was measured by radioimmunoassay employing the 30-K antibody of Unger (22) . Plasmla was treated with aprotinin (Trasylol) to prevent degradation of the glucagon. Plasma glucose concentration was determined by the glucose oxidase method employing a Beckman glucose analyzer (Beckman Instruments, Inc., Science Essentials Co., Mountainside, N. J.).
Data analysis
Data are presented as the mean + standard error of the means. Urinary electrolyte excretion, clearance values, and fractional excretion of electrolytes were calculated using standard formulas. The paired and unpaired t tests were employed in the statistical analyses (23) .
RESULTS
Human studies
In Fig. 1 , the effects of prolonged infusion of somatostatin on plasma glucose, insulin, and glucagon are showni for the healthy controls, maturity-onset diabetics, anid juvenile-onset diabetics. As expected (15, 24) , in the normal subjects and maturity-onset diabetics, somatostatin resulted in a prompt and sustained decline in plasma insulin of 56 and 63%, respectively. In all groups, plasma glucagon fell by 40-60%. Plasma glucose in the normal subjects and maturity-onset diabetics showed the previously described (15, 24) biphasic response characterized by an initial decline in blood glucose, followed by a subsequent rise to values 8-31 mg/100 ml above base line. In the juvenile-onset diabetics, blood glucose showed anl initial decline and then plateaued at 4-5 h.
Serum potassium concentration in the basal state was similar in the controls (4.02+0.08 meq/liter), the maturity-onset diabetics (3.88-+±0.09 meq/liter) and the juvenile-oniset diabetics (4.07±0.15 meq/liter). In Fig.   2 , the changes in serum potassium in response to infusion of somatostatin are shown. In the normal controls and maturity-onset diabetics serum potassium rose significantly above base-line values by 30 min (P < 0.01) and reached peak levels at 240 min. The maximum increase in serum potassium concentration was 0.57±0. 16 potassium occurred in the juvenile-onset diabetics (Fig. 2) .
Serum sodium concentration (139.6+0.6 meq/liter in the controls, 136.5+0.6 meq/liter in the maturity-onset diabetics, and 137.5+±0.9 meq/liter in the juvenileonset diabetics) was unaffected by the somatostatin infusion in any of the groups.
In Figs. 3 and 4 the effects of somatostatin on urinary excretion of potassium and sodium in the normal subjects are shown. Urinary potassium excretion was unchanged during somatostatin administration. In contrast, urinary sodium excretion fell by 26% during the first 120 min of the somatostatin infusion (P < 0.01), and then rose to values 59% above basal levels (P < 0.01) by the end ofthe infusion.
Creatinine clearance (121±6 ml/min in the basal state) was unchanged during the somatostatin infusion. The urine was free of glucose throughout the somatostatin infusion. FIGURE 2 The effect of somatostatin infuisioni oni the change in serum potassiumii conceintration in normal controls (@), maturity-onset diabetics (A), and juivenile-onset diabetics (U).
Studies in dogs
Basal potassium metabolism (Fig. 5) . After somatostatin the plasma insulin concentration declined from 20+1 to 11+1 -IAU/ml (P < 0.01) by 15 min and remained suppressed. Serum potassiumil concentration increased from 4 (Fig. 5) . In the three dogs given saliine n1o chainge in plasmia potassiumil concenitrationi was o0)-served during the 5-h infusioni.
Response in a fall in plasma insul.in which was prevented by the combined inftusioln of KCI, somatostatin, and insulin (Fig. 6 ). Plasma glucagon fell by 46±8% (P < 0.05) in the awake dogs during the combined somatostatin-KCI infusion but failed to decline or rose slightly in the anesthetized dogs receiving the combined somatostatin-KCl infuisionl. Fig. 6 . The maximumll rise in serum potassium after infusion of KCI alonie was 0.63±0.15 meq/liter. Addition of sonmatostatiin approximately doubled the rise in serum potassiumil to 1. 16±0).20 nmeq/liter (P < 0.01) without change in vei-cnous pH (7.35±)0.0(2 vs. 7.36±+(0.02) or bicarbonate (21±1.5 vs. 22±1.6 meq/liter). When insulin was a(l(le(l to the somatostatin infusion, the rise in serum potassiumii (0.40±0.15 meq/liter) was equivalent to that observed wvith KCl alone.
In the basal state, inulin clearanice was 69±6 ml/min anid PAH clearanice was 212±16 ml/min. Neither paramiieter was altere(d by KCl infusion with or without somatostatini.
After KCI alonie, the uriinary excretion of potassium (UKV) rose froImi a base line of 56±15 ,ueq/min to a maxiimiumii of 149±+24 ,eq/min at 240 min (Fig. 7) .
A similar rise in UKV from 72±14 to 184±8 ,ueq/min was observed after the combined KCl-somatostatin infusion. Changes in potassium clearance in dogs receiving KCI alone (14.3±3.6 to 32.7±5.0 ml/min), likewise, paralleled those in dogs receiving combined KCl-somatostatin infusion (20.6+3.6 to 37.3±2.9 ml/min). FIGURE 6 The effect of potassium chloride (KCl) infusion alone (E), KC1 plus somatostatin (SRIF) infusion (A), and KCI plus SRIF plus insulin (*) on plasma insulin concentration and the change in serum potassium concentration in dogs. FIGuRE 7 The effect of potassiumi chloride (KCI) infusion alone (0) and KCI pluis somiiatostatin (SRIF) infusion (A) on urinary potassium excretion.
plus somatostatin: 146±1 meq/liter;: statin plus insulin: 145±1 meq/litei serum sodium occurred in any of t mental groups. Base-line urine sodiu +68 ,ueq/min) and sodium clearance were unchanged by KCl alone (Fi addition of somatostatin resulted ir in sodium excretion UNaV at 60-12( This decline was followed by a rise 50% above basal at 240 min (P < 0 sodium clearance paralleled those of DISCUSSION The present findings demonstrate th basal insulin secretion by somatostq with an increase in serum potassiu in normal subjects and maturity-onse worthy is the fact that the rise in occurred before a rise in plasma gli absence of marked hyperglycemia That this effect of somatostatin is deficiency rather than glucagon 1 effect of this agent is suggested t (a) somatostatin failed to cause a ris( sium in juvenile-onset diabetics ii enous insulin secretion is marked plasma glucagon in juvenile-onse similarly to controls and maturity (Fig. 1) KCI plus somato-statin in normal dogs was overcome by conicommitant r). No change in insulin replacemiient (Fig. 5) . These data thus suggest the three experi-that basal insulini secretioni is an importaint factor in mn excretion (249 the nmainiteniance of the fLastiing plasmiia potassiumn con-(1.7±0.5 ml/min) centrationi within the normiial ranige. WVhen basal ig. 8). However, insulin secretioin is reducled (as with somiiatostatini a 64% decline admiiniistrationi) a rise in plasmiia potassiumil cani be ex-0 min (P = 0.08). pectecl even in the absence of nmarked hyperglycemia in U,,V to levels or voluimie contractioni. (6) . The present restults suggest that basal plasma insulin concentrations influence the net influx of potassium into cells. When the plasma insulin concentration is acutelv diminished below basal levels, as with somatostatin, there is a net movement of potassium out of cells or a failure of net uptake when exogenous potassium is administered, resulting in systemic hyperkalemia.
The possible clinical importance of the relationship between basal insulin secretion and potassium homeostasis is underscored by several recent reports of hyperkalemia in diabetic patients in the absence of uremia or acidosis (25, 26) . In some of the patients hyporeninemic-hypoaldosteronism has been identified as the major factor responsible for hyperkalemia (27, 28) . Other studies however, have demonstrated that the tendency to hyperkalemia may vary with the severity of the diabetics and may not be manifest despite a reduction in aldosterone secretion (25) . Indirect evidence that insulin lack contributes to the development of hyperkalemia in diabetes has been provided by studies demonstrating a hyperkalemic response to glucose infusion which is abolished by prior insulin administration (29) . The present findings suggest that insulin de- ficiency per se may be a contributory factor in the elevation of serum potassium concentration observed in some diabetic patients.
In addition to its actioni on potassium homeostasis, somatostatin had a biphasic effect on renal sodium excretion. An initial decline in urinary sodium was observed during the first 90 min, following by a progressive rise to values exceeding control levels. This pattern was observed in the healthy humans receiving somatostatin alone (Fig. 4) as well as in the anesthetized dogs receiving somatostatin plus KCI (Fig. 8) .
With respect to the mechanism of these changes in urinary excretion of sodium, the present data are compatible with a direct effect of somatostatin on renal tubular handling of sodium and/or hormoinally (insulin and glucagon) mediated changes in renal tubular handling of sodium. Although glucagon has been shown to have a natriuretic effect (14) , it is unlikely that hypoglucagoinemiiia was responsible for the initial fall in urine sodium since somatostatin failed to lower glucagon levels in the anesthetized dogs yet a transient decline in urinary sodium excretion was observed (Fig. 8) . With regard to the delayed increase in urine sodium loss, this may in part, be a consequence of the sodium chloride administered (50 ,ueq/min) as the vehicle for the somatostatini infusate. On the other hand, since physiologic increments in insulin have anl antinatriuretic effect (12, 13) the current data raise the possibility that urinary sodium excretion may be influenced by basal levels of insulin in the absence of which urinary sodium excretion may ultimately increase. Regardless of the mechanism involved, the effects of somatostatin onl sodium excretion do not appear to be mediated via changes in renal hemodynamics since inulin and PAH clearances were unaffected.
